Company Directory

Oral and injectable peptide therapies for obesity and cardiometabolic disease

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders. Its pipeline centres on rationally engineered peptide candidates acting on GLP-1 and amylin receptors, advanced through a proprietary oral absorption technology designed to enable once-weekly dosing. The lead programme is in Phase 2b clinical development, with earlier-stage amylin candidates in preclinical development for monotherapy and combination use.

UK affiliate of global family-owned biopharmaceutical company

Boehringer Ingelheim is a global family-owned biopharmaceutical company founded in 1885. Its Bracknell headquarters houses functions spanning research and development, regulatory affairs, pharmacovigilance, medical affairs, and commercial operations across its human pharma and animal health divisions. It operates across therapeutic areas including respiratory disease, cardiovascular disease, oncology, immunology, and metabolic disorders. It is a member of the ABPI and one of the largest pharmaceutical employers in Berkshire.

Microbiome modulator ingredients for metabolic health and disease prevention

OptiBiotix Health is a biotechnology company developing and licensing microbiome modulator products for use in food ingredients, dietary supplements, and nutraceuticals. Its portfolio includes patented prebiotic and probiotic formulations targeting weight management, cholesterol reduction, cardiovascular health, and gut microbiome diversity. Products are licensed to food and supplement manufacturers globally. The company operates through subsidiaries including OptiBiotix Ltd and holds a majority stake in SkinBioTherapeutics plc and ProBiotix Health Ltd.

Oral iron deficiency therapy for adults across multiple indications

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on iron deficiency. Its lead product, Accrufer/Feraccru (ferric maltol), is a non-salt-based oral iron therapy approved for the treatment of iron deficiency with or without anaemia in adults across the United States, European Union, United Kingdom, and Switzerland. The product is commercialised directly in the US via a partnership with Viatris, and licensed to Norgine for Europe, the UK, Australia and New Zealand.

AI-driven neural data platform for bioelectronic medicine

BIOS Health is a neural engineering company developing an AI-powered platform that reads and interprets peripheral nervous system signals in real time. Its technology links nerve activity to physiological conditions through the discovery of neural biomarkers, supporting the development of personalised neuromodulation therapies and neural digital therapeutics. BIOS serves pharmaceutical and medical device partners, academic research institutions, and NHS clinical programmes targeting cardiovascular, neurological, and autoimmune conditions.

Specialist CRO for ion channel screening and cardiac safety assessment

Metrion Biosciences is a contract research organisation specialising in preclinical ion channel biology, cardiac safety screening, and neuroscience drug discovery services. Founded in 2015 as a spin-out from Xention Limited, Metrion provides automated and manual patch clamp electrophysiology, GLP-compliant hERG testing, CiPA cardiac ion channel panel screening, and translational neuroscience assays. It serves pharmaceutical and biotechnology companies globally on a fee-for-service or collaborative basis from its laboratories at Granta Park, Cambridge.

Perfluorocarbon oxygen carrier therapeutic and MRI imaging agent for acute stroke

Aurum Biosciences is a Scottish clinical-stage biopharmaceutical company developing ABL-101, a perfluorocarbon-based oxygen carrier that bypasses arterial clots to deliver oxygen to ischaemic tissue via collateral vessels. The lead indication is acute ischaemic stroke, with ABL-101 having completed Phase 1 and 2a human studies under MHRA approval. The company has also developed GOLD, a proprietary MRI metabolic imaging technique using ABL-101 to identify salvageable brain tissue, and a 19F MRI platform for inflammation imaging.

RNA sequencing liquid biopsy for cardiovascular and complex disease screening

MultiplAI Health is a Cambridge biotech developing a whole-blood RNA sequencing test for early screening of cardiovascular and other complex diseases. Its platform combines transcriptomic profiling of blood samples with a patented data transformation process and proprietary deep learning algorithms to generate precision risk assessments from a single blood draw. The technology is designed for universal, affordable, remote screening of asymptomatic individuals, enabling proactive cardiovascular risk management.

Single-pill fixed-dose combinations for cardiometabolic disease

George Medicines is a late-stage biopharmaceutical company developing innovative single-pill, fixed-dose combination therapies for cardiometabolic diseases. Rather than pursuing early drug discovery, the company reformulates established best-in-class small molecules into novel proprietary low-dose combinations designed to improve efficacy, safety, and treatment adherence. Its lead programme is a triple combination therapy for hypertension that has completed two pivotal Phase III trials with positive data, and is being commercialised across multiple international markets.

Blood-based liquid biopsy for endothelial glycocalyx and microvascular health

Dimension Biotechnologies is a biotech developing a rapid, blood-based diagnostic for microvascular health based on analysis of the endothelial glycocalyx, the molecular layer lining blood vessel walls whose biochemical integrity is disrupted early in cardiovascular disease, kidney disease, diabetes, and sepsis. The platform detects glycocalyx biomarker signatures from a blood sample using spectroscopic methods compatible with existing laboratory equipment, enabling non-invasive assessment of microvascular health for clinical prognostics and drug development research.

Isoform-specific antibody therapeutics for vascular disease

IsomAb is a biotechnology company developing isoform-specific antibody therapeutics for serious vascular diseases. Its lead programme, ISM-001, targets VEGF-A165b, an anti-angiogenic splice isoform implicated in peripheral arterial disease and chronic limb-threatening ischaemia. The company uses a bioinformatics-guided platform to identify pathogenic mRNA splicing targets and develop disease-modifying antibodies for conditions with limited treatment options. ISM-001 is currently in IND-enabling preclinical studies.

Lateral flow and molecular diagnostic tests for multiple applications

AccuBio is a UK-based manufacturer of in-vitro diagnostic products, producing lateral flow assays and molecular diagnostic tests across infectious disease, toxicology, oncology, cardiovascular, and veterinary applications. Operating from manufacturing facilities in Alva, Scotland, acquired from Omega Diagnostics, the company supplies healthcare providers, laboratories, and veterinary services globally. AccuBio is a wholly owned subsidiary of Healgen Scientific, a US-based IVD group within the broader Zhejiang Orient Gene Biotech group.